Currently, both chronic pain diseases and depressive disorders lack methods for objective evaluation in the clinic, and the techniques to investigate mGluR5 level in the brain is considered to be a promising approach for the assessment of the pain and/or depression in clinical trials. Here, GRM5 is linked to depressive symptom measurement.